Synlogic Inc (NAS:SYBX)
$ 1.4465 0.0565 (4.06%) Market Cap: 16.92 Mil Enterprise Value: -3.05 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 58/100

Synlogic Inc Clinical Program Update Call Transcript

Sep 20, 2021 / 12:30PM GMT
Release Date Price: $55.65 (+12.77%)
Operator

Good morning. Welcome to Synlogic's Clinical Program Update Call. (Operator Instructions) Please be advised that this call is being recorded. I would now like to turn the call over to Daniel Rosan, Head of Finance and Investor Relations. Please proceed.

Daniel Rosan
Synlogic, Inc. - Senior VP, Head of Finance & IR

Thank you, operator. Good morning, everybody, and thank you for joining us on today's conference call. This morning, we issued a press release, which outlines progress in our phenylketonuria program and additional business updates. This release is available on the Investors section of our website at synlogictx.com.

Joining me this morning are Dr. Aoife Brennan, President and Chief Executive Officer; and Dr. David Hava, Chief Scientific Officer. Other members of the Synlogic management team will be available during the Q&A.

Before we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot